Internal restructuring
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Chemicals And Chemical Products
20 - Manufacture of chemicals and chemical products

284 jobs
Number of planned job losses
Job loss
Announcement Date
9 November 2016
Employment effect (start)
2 January 2017
Foreseen end date
31 December 2017


The Japanese pharmaceutical group Daiichi Sankyo has announced a reorganisation in France that will lead to cut 284 positions on a total of 303. The management has started discussion with unions on the employment safeguard plan. The group will dismiss all the sales representatives and 67 positions in its headquarter at Rueil-Malmaison (Haut-de-Seine). According to the union CGT, the decision is only based on financial and stock exchanges considerations. The management explains the decision is a reaction to the termination of the reimbursement of one of its main drugs by the French social security, which will lead to a drop of sales. Furthermore, the French health authority has decided to postpone the agreement to sell a new drug (Lixiana) on the French market. The group expects a loss of  €15 million in France in 2017. The unions have decided to build a common front and to organise a strike on 24 November. In 2013, the group launched a voluntary departure plan that led to 160 departures and 6 forced dismissals.


  • 9 November 2016: La Croix
  • 9 November 2016: Ouest-France


Eurofound (2016), Daiichi Sankyo France, Internal restructuring in France, factsheet number 89078, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/89078.